Anti–Peptidylarginine Deiminase 4 Autoantibodies Derived From Patients With Rheumatoid Arthritis Exert Pathogenic Effects by Activating Monocytes and Exacerbating Inflammatory Arthritis
Arthritis & Rheumatology · 2025-09 · 77 (9) · 1150-1165
DOI: 10.1002/art.43168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 27.05.2025. Verfasst von Taejoon Won und 14 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, Baltimore, Maryland, and College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Monocytes, Autoantibodies, Protein-Arginine Deiminase Type 4. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Bristol Myers Squibb, NIH HHS, NIAMS, NIH.
Abstract (Originalsprache)
Objective
Autoantibodies targeting peptidylarginine deiminase 4 (PAD4), an enzyme involved in protein citrullination, are found in a subset of patients with rheumatoid arthritis (RA) with severe joint disease. However, the mechanisms by which anti‐PAD4 antibodies participate in disease pathogenesis are incompletely defined.
Methods
We investigated the role of anti‐PAD4 monoclonal antibodies derived from patients with RA using a collagen‐induced arthritis (CIA) mouse model and human monocyte in vitro cultures. The cellular targets of anti‐PAD4 antibodies were identified using mouse knee joint cells and human peripheral blood mononuclear cells. In addition, PAD4 gene and protein expression was assessed using human fibroblast‐like synoviocyte in vitro cultures and a single‐cell RNA sequencing data set obtained from patients with RA.
Results
We show that anti‐PAD4 antibody treatment augmented disease severity in the CIA mouse model, with increased joint damage, myeloid cell infiltration, and synovial fibroblast activation. Arthritic mice administered with anti‐PAD4 antibodies had an increased proportion of interleukin‐17A (IL‐17A), tumor necrosis factor α (TNFα), and interferon‐γ (IFNγ)–producing T cells. Anti‐PAD4 antibodies preferentially bound monocytes in both humans and mice, eliciting proinflammatory chemokine production by human monocytes in vitro. T cell cytokines enhanced by anti‐PAD4 antibodies in the CIA model (ie, IL‐17A, TNFα, and IFNγ) synergized to induce a proinflammatory phenotype in human fibroblast‐like synoviocytes.
Conclusion
Our findings suggest a model in which anti‐PAD4 antibody binding to monocytes triggers an inflammatory cascade that promotes immune cell recruitment to the joint and T cell activation, culminating in synovial fibroblast activation and the development of more severe arthritis. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Johns Hopkins University School of Medicine, Baltimore, Maryland, and College of Veterinary Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois.
- Johns Hopkins University School of Medicine, Baltimore, Maryland.
ORCID-Profile: Taejoon Won, Mekha A Thomas, Felipe Andrade, Daniela Čiháková, Erika Darrah
Förderung
- Bristol Myers Squibb
- NIH HHS
- NIAMS, NIH
- NHLBI NIH HHS
- American Heart Association
- NIAMS NIH HHS
- the National Heart, Lung, and Blood Institute, NIH
- the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Zitieren
APA
Won, T., Naik, P., Wood, M. K., Wang, H., Talor, M. V., Shi, J., Bracamonte-Baran, W., Thomas, M. A., Jaime, C. M., Jo, W., Ray, S., Foss, C. A., Andrade, F., Čiháková, D., & Darrah, E. (2025). Anti–Peptidylarginine Deiminase 4 Autoantibodies Derived From Patients With Rheumatoid Arthritis Exert Pathogenic Effects by Activating Monocytes and Exacerbating Inflammatory Arthritis. Arthritis & Rheumatology, 77(9), 1150-1165. https://doi.org/10.1002/art.43168
Vancouver
Won T, Naik P, Wood MK, Wang H, Talor MV, Shi J, et al. Anti–Peptidylarginine Deiminase 4 Autoantibodies Derived From Patients With Rheumatoid Arthritis Exert Pathogenic Effects by Activating Monocytes and Exacerbating Inflammatory Arthritis. Arthritis & Rheumatology. 2025;77(9):1150-1165. doi:10.1002/art.43168
BibTeX
@article{Won2025,
author = {Won, Taejoon and Naik, Pooja and Wood, Megan K and Wang, Hong and Talor, Monica V and Shi, Jing and Bracamonte-Baran, William and Thomas, Mekha A and Jaime, Camille M and Jo, Wonyoung and Ray, Shreyanshu and Foss, Catherine A and Andrade, Felipe and Čiháková, Daniela and Darrah, Erika},
title = {Anti–Peptidylarginine Deiminase 4 Autoantibodies Derived From Patients With Rheumatoid Arthritis Exert Pathogenic Effects by Activating Monocytes and Exacerbating Inflammatory Arthritis},
journal = {Arthritis & Rheumatology},
year = {2025},
volume = {77},
number = {9},
pages = {1150--1165},
doi = {10.1002/art.43168}
}
EUVIMED